The cancer therapy developer boosted its overall funding to more than $200m in a round that included series A backer Takeda Ventures.
US-based cancer drug developer VelosBio closed a $137m series B round yesterday that included pharmaceutical firm Takeda’s corporate venturing unit, Takeda Ventures.
Hedge fund manager Matrix Capital Management co-led the round with Surveyor Capital, a subsidiary of investment manager Citadel. It increased VelosBio’s overall funding to $202m since it was founded in 2017, the company said.
The round included Adage Capital Management, Cormorant Asset Management, Farallon, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed, Venrock Healthcare Capital Partners, Viking Global…
